CTEPH

Dr. Yuko Yamasaki Receives RSNA’s Cum Laude Award for Dynamic Digital Radiography Education Exhibit During Annual Meeting

Retrieved on: 
Wednesday, December 21, 2022
Education, DCR, Editorial, Motion, MD, Research, Anatomy, Pulmonology, Radiological Society of North America, CTEPH, Kyushu University, DDR, Latin honors, RSNA, Radiation, CT, Nuclear medicine, Correlation and dependence, Minolta, Senior, Doctor of Philosophy, Agent handling, Medical imaging, Radiology, Marketing

Dr. Yamasaki’s education exhibit, “Dynamic Chest Radiography for Pulmonary Vascular Diseases: Clinical Applications and Correlation with Other Imaging Modalities,” was one of 43 Cum Laude awards given to the 1,454 education exhibits presented at RSNA 2022, and one of only five X-ray-focused presentations to receive an award this year.

Key Points: 
  • Dr. Yamasaki’s education exhibit, “Dynamic Chest Radiography for Pulmonary Vascular Diseases: Clinical Applications and Correlation with Other Imaging Modalities,” was one of 43 Cum Laude awards given to the 1,454 education exhibits presented at RSNA 2022, and one of only five X-ray-focused presentations to receive an award this year.
  • DDR is an evolution in radiographic technology that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.
  • Dr. Yamasaki’s education exhibit discussed the advantages of DCR (aka DDR) compared to other imaging modalities for lung perfusion and ventilation assessment.
  • “Konica Minolta congratulates Dr. Yamasaki for his excellent work and educational exhibit on the use of DDR for evaluating pulmonary diseases.

Sky View Suites & StayWell Announce Long-Term Partnership

Retrieved on: 
Tuesday, December 20, 2022
Hospital, Heart failure, Patient, Family, CTEPH, Partnership, Growth, Chronic thromboembolic pulmonary hypertension, Toronto General Hospital, Caregiver, Artery, Health insurance, Communications satellite

StayWell and Sky View Suites are proud to announce a long-term partnership that is expected to support patient accommodations across Canada.

Key Points: 
  • StayWell and Sky View Suites are proud to announce a long-term partnership that is expected to support patient accommodations across Canada.
  • The partnership leverages the respective strengths of StayWell and Sky View Suites to help expand access and improve service to patients relocating for medical treatment.
  • StayWell and Sky View Suites announce a five-year partnership that to support patient accommodations across Canada.
  • – Sass Khazzam – StayWell CEO
    Together, StayWell and Sky View Suites have changed the lives of many, and saved the lives of some.

Study Reports Similar Efficacy of Dynamic Digital Radiography of the Chest with Lung Ventilation Perfusion for Detection of Chronic Thromboembolic Pulmonary Hypertension

Retrieved on: 
Tuesday, November 22, 2022
Doctor of Philosophy, Editorial, Medicine, WHO, Diagnosis, Lung, Society for Imaging Science and Technology, University, DCR, Nuclear medicine, Digital radiography, Physician, Mortality, Patient, Agent handling, Comment, Radiological Society of North America, Graduate school, MD, Disease, World Health Organization, MRI, Pulmonary hypertension, Senior, Innovation, Weill Cornell Graduate School of Medical Sciences, University of Rochester Medical Center, Assistant, Konica Minolta, Pulmonary embolism, Research, CTEPH, Motion, Kyushu University, CT, DDR, Medical imaging, Marketing, Radiology

Dynamic Digital Radiography is a radiographic technique that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.

Key Points: 
  • Dynamic Digital Radiography is a radiographic technique that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.
  • CTEPH is a complication of pulmonary embolism and a significant cause of pulmonary hypertension with associated morbidity and mortality if left untreated.
  • As a potentially treatable cause of pulmonary hypertension, identification of CTEPH with imaging may significantly impact clinical outcomes of patients with this condition.
  • Each patient also had conventional chest radiography and underwent a lung V/Q study on a SPECT/CT system with intravenous injection of technetium-99m macroaggregated albumin, 185 MBq.

November is PH Awareness Month. Learn About Pulmonary Hypertension Day by Day with Interactive Calendar

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, International, LinkedIn, Caregiver, Congress, Time, Sleep apnea, Disease, COPD, Fatigue, Future, Conference, Diagnosis, Pulmonary hypertension, CTEPH, Pulmonary Hypertension Association, Canada (AG) v PHS Community Services Society, Education, Patient, Scleroderma, Research, Twitter, Instagram, PHA, Facebook, Chest pain, Awareness, Embolism, Sex, Ventricular septal defect, American Lung Association, Adult, Social media, COPD Awareness Month, Association, Health, EST, Death, Calendar, Chronic obstructive pulmonary disease, Trustee, Future Together, Risk, Vanderbilt University Medical Center, Leadership, Pharmaceutical industry, Health insurance

WASHINGTON, October 11, 2022 /PRNewswire-PRWeb/ -- Each November, the Pulmonary Hypertension Association (PHA) launches a national campaign to raise awareness about pulmonary hypertension (PH). This progressive rare disease is defined by high blood pressure in the lungs and can cause right-heart failure and even death.

Key Points: 
  • The Pulmonary Hypertension Association's "PHacing the Future Day by Day" campaign strives to educate people about pulmonary hypertension through an interactive online calendar.
  • WASHINGTON, October 11, 2022 /PRNewswire-PRWeb/ -- Each November, the Pulmonary Hypertension Association (PHA) launches a national campaign to raise awareness about pulmonary hypertension (PH).
  • Throughout November, PHA will educate people about risk factors and symptoms of PH through its award-winning interactive, online PH Awareness Month calendar.
  • The calendar reveals a new fact or tool daily, along with downloadable resources to raise PH awareness.

ISHLT Annual Meeting and Scientific Sessions to Convene International Transplant Community Next Month

Retrieved on: 
Tuesday, March 1, 2022
CAE, Pediatrics, Transplant, Abstract (summary), Research, MA, PAH, Convention, Patient, Heart, Lung transplantation, Critical care, Industry, CME, Annual Meetings of the International Monetary Fund and the World Bank Group, Society, Pathology, Scientific programming language, Professional communication, Doctor of Philosophy, Safety, CTEPH, Annual, Solution, Anesthesiology, APN, Multimedia, COVID-19, MBBS, MRCP, 2021 Essex County Council election, MHS, International Society, MCS, Schedule, Cardiology, Lecture, Annual general meeting, Education, Review, Technology, MD, III, List of lifetime achievement awards, FAAN, International Society for Heart and Lung Transplantation, Health, Pharmacology, Infection, Medical device, Book, Pharmaceutical industry, Dentistry, Medicine, Online shopping, Immunology, Pulmonology, Nursing, Breakfast, Pharmacy

ADDISON, Texas, March 1, 2022 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) will host its 42nd Annual Meeting and Scientific Sessions on 27-30 April, 2022.

Key Points: 
  • ADDISON, Texas, March 1, 2022 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) will host its 42nd Annual Meeting and Scientific Sessions on 27-30 April, 2022.
  • Attendees will meet in Boston, MA USA, marking the first time the ISHLT community has met in person since 2019.
  • "The 42nd Annual Meeting and Scientific Sessions of the ISHLT offers a unique and exciting opportunity to hear about the latest advances in heart and lung disease, as well as transplantation," says Laurie Snyder, MD, MHS, ISHLT 2022 Scientific Program Chair.
  • Sessions include 36 symposia, three plenary sessions, 18 sunrise symposia, 46 oral abstract sessions, and 18 mini oral abstract sessions.

Inari Medical Announces 6-month FLASH Registry Interim Data Demonstrating Benefits of Lytic-Free Mechanical Thrombectomy in 500 Real-World PE Patients

Retrieved on: 
Thursday, October 28, 2021
Safety, MD, Quality of life, VTE, University, Hemodynamics, Disease, University of Pittsburgh Medical Center, CTEPH, TCT, Patient, Inari, NASDAQ, FDA, Breathe Me, PE, ICU, UPMC, FLASH, Deep vein thrombosis, Principal investigator, Interventional cardiology, CE, Thrombosis, Death, Mortality, GLOBE, Pulmonary embolism, Medical imaging

At 48 hours post procedure, the major adverse event rate and mortality rate were low, at 1.4% and 0.2%, respectively.

Key Points: 
  • At 48 hours post procedure, the major adverse event rate and mortality rate were low, at 1.4% and 0.2%, respectively.
  • Collectively, these PE patients experienced substantial on-table improvements in hemodynamics and symptoms, which translated to 6-month improvements in cardiac function, functional status, and quality of life measures.
  • FLASH is a prospective, multicenter, single-arm registry evaluating real-world patient outcomes after treatment of PE with FlowTriever.
  • Inari Medical, Inc. is a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.

November is PH Awareness Month; Learn About Pulmonary Hypertension With Daily Facts

Retrieved on: 
Thursday, October 21, 2021
Death, PH, Research, Diagnosis, Chest pain, Quality of life, LinkedIn, Disease, Awareness, COPD, CTEPH, Twitter, Scleroderma, Caregiver, Patient, Calendar, PHA, Trustee, Chronic obstructive pulmonary disease, Ventricular septal defect, Pulmonary hypertension, Pulmonary Hypertension Association, Risk, Time, Adult, Social media, Instagram, Fatigue, Facebook, Health, Embolism, Association, Sleep apnea, Pharmaceutical industry, Public relations, Birth control

SILVER SPRING, Md., Oct. 21, 2021 /PRNewswire-PRWeb/ -- Each November, the Pulmonary Hypertension Association (PHA) launches a national campaign to raise awareness about pulmonary hypertension (PH).

Key Points: 
  • SILVER SPRING, Md., Oct. 21, 2021 /PRNewswire-PRWeb/ -- Each November, the Pulmonary Hypertension Association (PHA) launches a national campaign to raise awareness about pulmonary hypertension (PH).
  • Throughout November, PHA will educate people about risk factors and symptoms through an interactive PH Awareness Month calendar.
  • The calendar reveals a new fact or tool daily, along with downloadable resources to Spark Awareness of PH.
  • More information about PH, the campaign, and how to Spark Awareness can be found at: http://www.phassociation.org/awarenessmonth
    Headquartered in Silver Spring, Md., the Pulmonary Hypertension Association (PHA) is the country's oldest and largest nonprofit patient association dedicated to the pulmonary hypertension (PH) community.

Inari Medical Appoints Pulmonologist Dr. Victor F. Tapson as VP of Medical Affairs

Retrieved on: 
Tuesday, September 21, 2021
Thrombosis, VTE, Pulmonary hypertension, Degenerative disease, Medical Affairs Bureau, Education, Diagnosis, Program, Lung transplantation, Duke University Hospital, NASDAQ, FDA, Pulmonary embolism, Deep vein thrombosis, Patient, CTEPH, Health, Â, CA, Medicine, Critical care, Annals of the American Thoracic Society, Gold, Cedars, Research, VP, Cedars-Sinai Medical Center, Drexel University School of Public Health, Internal medicine, CE marking, PERT, GLOBE, Medical device

Dr. Tapson has devoted his medical career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism.

Key Points: 
  • Dr. Tapson has devoted his medical career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism.
  • I am thrilled to be joining Inari Medical on its mission to revolutionize the treatment of pulmonary embolism and deep venous thrombosis, said Dr. Tapson.
  • Prior to Inari, Dr. Tapson was in practice at Cedars-Sinai Medical Center in Los Angeles, CA where he started the first Pulmonary Embolism Response Team (PERT) on the west coast.
  • Inari Medical, Inc. is a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.